Country operational research priorities pending.
- Can the micro-stratification of lymphatic filariasis (LF) transmission assessment surveys positive case and clinical case data be used to identify, map and monitor transmission hotspots as part of an enhanced endgame surveillance strategy?
- Can targeted molecular xenomonitoring detect ongoing transmission [to the same extent as human surveillance] in defined LF transmission hotspots?
This study aims to determine if the addition of lymphatic stimulating activities to community-based home-care for lymphoedema can improve outcomes for people affecetd by moderate to late stage disease.
To determine if a standardized multi-parallel-PCR assay is a more sensitive diagnostic tool for detecting Hookworm, Trichuris trichiura, Ascaris lumbricoides, and Strongyloides prevalence compared to the Kato-Katz stool test.
To evaluate the utility of ongoing surveillance of adults in a post-treatment setting.
To determine if post-treatment surveillance of adults represents a more effective surveillance strategy than TAS or xenomonitoring.
To compare the sensitivity of double-slide Kato-Katz and multi-parallel real-time polymerase chain reaction (PCR) in the detection of Ascaris, hookworm, and Trichuris infection among children in rural Bangladesh
Mass drug administration (MDA) programs have dramatically reduced lymphatic filariasis (LF) incidence in many areas around the globe, including Bangladesh. Post-treatment surveillance activities as recommended by WHO include repeated transmission assessment surveys (TAS) among children and ongoing surveillance to detect new foci of transmission and collect data on infection trends in the general population. The contribution of molecular xenomonitoring (MX, or detection of filarial DNA in mosquitoes) to confirm the interruption of transmission during the post-treatment surveillance phase has not been well defined. There is also a need to better understand the relationship between the prevalence of W. bancrofti DNA in mosquitoes and infection in humans.
To implement a new re-mapping strategy for LF in low-prevalence areas.